July 7 (Reuters) - Obesity-focused clinical-stage biotechnology company Kalohexis on Tuesday confidentially filed to go public in the U.S., adding to an activity rebound in the initial public offering ...

Quick ReadJim Cramer predicts a biotech takeover flood, with Lilly posting $19.8B Q1 revenue and Gilead closing a $7.8B ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

United Therapeutics, a biotechnology company with co-headquarters and manufacturing facilities in Research Triangle Park, has acquired a Boston-area biotech company to boost its efforts in ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...